Antiangiogenic Factors in Gastric Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Endogenous antiangiogenic factors are related with gastric cancer progression.
| Condition |
|---|
|
Gastric Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression |
- Relationship between antiangiogenic factor and tumor, node, metastasis [ Time Frame: One year ] [ Designated as safety issue: No ]
- Overall survival, treatment failure [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Serum for protein assay using ELISA
| Enrollment: | 240 |
| Study Start Date: | April 2006 |
| Study Completion Date: | January 2012 |
| Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in vivo. Tumor VEGF expression is correlated with the severity of disease in patients with gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in humans, the generation of antiangiogenic compounds in the presence of a primary tumor suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However, the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not been reported.
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Eligible patients will undergo subtotal or total gastrectomy with D2 lymph node dissection
Inclusion Criteria:
- Histologic diagnosis of gastric adenocarcinoma
- No other forms of cancer therapy, such as chemotherapy or radiotherapy for at least 3 weeks before the enrollment in study
- Performance status of 0, 1, 2 on the ECOG criteria
- ASA class I, II
- Patient compliance that allow adequate follow up
- Informed consent from patient or patient's relative.
Exclusion Criteria:
- Second primary malignancy
- EMR (Endoscopic mucosal resection) indication
- Laparoscopic gastrectomy
- Radiologic or clinical evidence of metastasis
Contacts and Locations| Korea, Republic of | |
| National Cancer Center | |
| Goyang-si, Geonggi-do, Korea, Republic of, 410-0769 | |
| Principal Investigator: | Jun Ho Lee, M.D., Ph.D | Gastric Cancer Branch, National Cancer Center |
More Information
No publications provided
| Responsible Party: | Jun Ho Lee, Staff Surgeon, National Cancer Center, Korea |
| ClinicalTrials.gov Identifier: | NCT00735566 History of Changes |
| Other Study ID Numbers: | NCCCTS 04-105 |
| Study First Received: | August 13, 2008 |
| Last Updated: | October 16, 2012 |
| Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
Keywords provided by National Cancer Center, Korea:
|
gastric cancer antiangiogenic factors TNM stage |
Additional relevant MeSH terms:
|
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases |
Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Pharmacologic Actions Growth Inhibitors Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013